Lobeglitazone (LB) is a novel dual agonist of PPAR-α and γ; it has a higher affinity for PPAR-γ than for PPAR-α, for which it has partial affinity, and is used for the management of type 2 diabetes mellitus (Kim et al., 2011; Lim et al., 2015). Here, PPARA is linked to type 2 diabetes mellitus.